{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:46:20Z","timestamp":1792431980289,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ygyno.2015.03.005","type":"journal-article","created":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T21:45:24Z","timestamp":1426023924000},"page":"216-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia"],"prefix":"10.1016","volume":"137","clinical-trial-number":[{"clinical-trial-number":"nct01175343","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01292655","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01986218","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ivan","family":"Diaz-Padilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaise A.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal W.","family":"Hirte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim J.","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reedijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne I.","family":"Weberpals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantale","family":"Blattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-072X","authenticated-orcid":false,"given":"S. Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.03.005_bb0005","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.tcb.2005.07.004","article-title":"Cancer stem cells: lessons from leukemia","volume":"15","author":"Wang","year":"2005","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4161\/cc.8.1.7533","article-title":"Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance","volume":"8","author":"Alvero","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0025","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1073\/pnas.1005529108","article-title":"Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells","volume":"108","author":"Stewart","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0240","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-05-3153","article-title":"Cancer stem cells: an old idea\u2014a paradigm shift","volume":"66","author":"Wicha","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1756-9966-32-48","article-title":"Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach","volume":"32","author":"Tomao","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0040","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-11-2188","article-title":"Stem cell pathways contribute to clinical chemoresistance in ovarian cancer","volume":"18","author":"Steg","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0045","doi-asserted-by":"crossref","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","article-title":"Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy","volume":"109","author":"McAuliffe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0245","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0055","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/j.1349-7006.2010.01641.x","article-title":"Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma","volume":"101","author":"Jung","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0060","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.284.5415.770","article-title":"Notch signaling: cell fate control and signal integration in development","volume":"284","author":"Artavanis-Tsakonas","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0065","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/emboj\/20.13.3427","article-title":"Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation","volume":"20","author":"Rangarajan","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0070","doi-asserted-by":"crossref","first-page":"7787","DOI":"10.1158\/0008-5472.CAN-04-1446","article-title":"Notch1 and notch2 have opposite effects on embryonal brain tumor growth","volume":"64","author":"Fan","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0250","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1158\/0008-5472.CAN-13-2066","article-title":"Notch3 pathway alterations in ovarian cancer","volume":"74","author":"Hu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0080","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1309\/AJCPKDLRQ8F3EWNS","article-title":"Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer","volume":"138","author":"Rahman","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0085","first-page":"943","article-title":"Gamma secretase inhibitors of Notch signaling","volume":"6","author":"Olsauskas-Kuprys","year":"2013","journal-title":"Oncol. Targets Ther."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0090","first-page":"801","article-title":"The role of Notch and gamma-secretase inhibition in an ovarian cancer model","volume":"33","author":"Shah","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0095","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1158\/0008-5472.CAN-09-1843","article-title":"Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties","volume":"69","author":"Luistro","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2011.36.8282","article-title":"Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors","author":"Tolcher","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0105","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1200\/JCO.2012.42.3277","article-title":"Moving forward one Notch at a time","volume":"30","author":"Gounder","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0260","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0125","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1158\/0008-5472.CAN-05-1069","article-title":"High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival","volume":"65","author":"Reedijk","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0130","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jcb.24317","article-title":"Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance","volume":"114","author":"Ahmed","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0145","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4161\/cbt.22007","article-title":"Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate","volume":"13","author":"Wintzell","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-12-24","article-title":"Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden","volume":"12","author":"Abubaker","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0155","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1200\/JCO.2012.42.0992","article-title":"Targeting the Notch pathway: twists and turns on the road to rational therapeutics","volume":"30","author":"Aster","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0160","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1200\/JCO.2011.39.1540","article-title":"Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors","volume":"30","author":"Krop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0165","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s10637-013-0001-5","article-title":"A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors","volume":"31","author":"Diaz-Padilla","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0170","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/B978-0-12-397927-8.00007-5","article-title":"Targeting Notch signaling for cancer therapeutic intervention","volume":"65","author":"Shao","year":"2012","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0180","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1476-4598-10-138","article-title":"Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation","volume":"10","author":"Vo","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0185","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1158\/1078-0432.CCR-11-3326","article-title":"Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors","volume":"19","author":"Schott","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0190","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fonc.2014.00171","article-title":"Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth","volume":"4","author":"Groeneweg","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0195","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13048-014-0095-1","article-title":"Notch signaling in serous ovarian cancer","volume":"7","author":"Groeneweg","year":"2014","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0200","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1158\/1078-0432.CCR-11-0432","article-title":"Targeting the Notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer","volume":"17","author":"Steg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0205","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2353\/ajpath.2010.100316","article-title":"Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin","volume":"177","author":"Park","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0210","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/IGC.0000000000000359","article-title":"Increased notch1 expression is associated with poor overall survival in patients with ovarian cancer","volume":"25","author":"Alniaimi","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0215","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.devcel.2009.01.015","article-title":"Angiogenesis: a team effort coordinated by notch","volume":"16","author":"Phng","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0220","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pharmthera.2013.09.005","article-title":"Targeting notch signaling pathway in cancer: clinical development advances and challenges","volume":"141","author":"Takebe","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0225","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/nature05313","article-title":"Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis","volume":"444","author":"Ridgway","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.03.005_bb0230","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/0008-5472.CAN-10-2719","article-title":"Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer","volume":"71","author":"Hu","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.005_bb0235","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/1078-0432.CCR-10-1791","article-title":"Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer","volume":"17","author":"Jubb","year":"2011","journal-title":"Clin. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815006800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815006800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:36:39Z","timestamp":1758771399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815006800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0090825815006800"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}